"Pfizer Inc and BioNTech's COVID-19 vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa，according to a laboratory study conducted by the U.S. drugmaker.
The study by Pfizer and scientists from the University of Texas Medical Branch (UTMB), which has not yet been peer-reviewed, showed a less than two-fold reduction in antibody titer levels, indicating the vaccine would likely be effective in neutralizing a virus with the so-called E484K and N501Y mutations found in the South African variant.
The study here was conducted on blood taken from people who had received the vaccine. "
可扣细节，看到大坑了："an engineered virus with three key mutations from the new coronavirus variant found in South Africa"
所用的病毒是按南非变种，人工合成的！！！
更糟的是，作者们滋滋不倦的还要接着合成
"The scientists are currently engineering a virus with the full set of mutations and expect to have results from that in around two weeks, according to Pei-Yong Shi, an author of the study and a professor at UTMB."
.........
"The study also showed even better results against several key mutations from the highly transmissible UK variant of the virus. Shi said they were also working on an engineered virus with the full set of mutations from that variant as well."
We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.
Three recombinant SARS-CoV-2 mutants (N501Y, 102 Δ 69/70-N501Y+D614G, E484K+N501Y+D614G in spike protein) were prepared on the genetic 103 background of an infectious cDNA clone derived from clinical strain WA1 (2019- 104 nCoV/USA_WA1/2020) 5 by following the PCR-based mutagenesis protocol as reported 105 previously 7 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 .”
晨起，迷迷糊糊，扫过一篇报道。咋看，觉得是好消息。闭眼一想，有点不对劲。再琢磨，毛骨悚然。
报道：https://mobile.reuters.com/article/amp/idUSKBN29W31
标题：Pfizer vaccine only slightly less effective against key South African mutations - study
从标题看，是个好消息: vaccine will still work against these new variants.
下面一段文中提到怎么得出这个结论的：用疫苗接种者身上诱导出来的抗体对病毒的中和滴定度来评估其有效性。
"Pfizer Inc and BioNTech's COVID-19 vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa，according to a laboratory study conducted by the U.S. drugmaker.
The study by Pfizer and scientists from the University of Texas Medical Branch (UTMB), which has not yet been peer-reviewed, showed a less than two-fold reduction in antibody titer levels, indicating the vaccine would likely be effective in neutralizing a virus with the so-called E484K and N501Y mutations found in the South African variant.
The study here was conducted on blood taken from people who had received the vaccine. "
可扣细节，看到大坑了："an engineered virus with three key mutations from the new coronavirus variant found in South Africa"
所用的病毒是按南非变种，人工合成的！！！
更糟的是，作者们滋滋不倦的还要接着合成
"The scientists are currently engineering a virus with the full set of mutations and expect to have results from that in around two weeks, according to Pei-Yong Shi, an author of the study and a professor at UTMB."
.........
"The study also showed even better results against several key mutations from the highly transmissible UK variant of the virus. Shi said they were also working on an engineered virus with the full set of mutations from that variant as well."
俺就搞不明白，这位'德大'（UTMB)的“Shi"到底咋想的呢？难道没看到武汉那个水深火热中的“石”？
还是想要证明其实验室比“石”厉害，有本事整出各种病毒？！
可万一，脑子一迷胡，手抖了一下，加错点啥，或按差了键，整出些更邪乎的新变种。
再不小心逛街时放个屁，嘣出来几个……………
这世界岂不更精彩。
这秧秧大国，咋就没人管这事呢？
请德大的朋友，转告那位Shi:
一念天堂 一念地狱 (the difference between heaven and hell lies in your way of thinking)
阿弥陀佛
再生元的抗体不是说对变异有效吗？为什么昨天其股票也大跌呢？
看fine print，有效的报告没有经过peer review，大家不信？
是使用病人血清，筛选的抗原优化加上免疫人源性小鼠的抗体library 筛选出来的2个组合抗体鸡尾酒，可以确保两个抗体cover病毒的不同位点，应对突变。
You need to engineer virus to produce vaccine. There is nothing evil here, just pure science..
https://www.biomart.cn/experiment/3324.htm
https://www.biorxiv.org/content/10.1101/2021.01.27.427998v1
AbstractWe engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.
（以We开头，得多么自信自豪啊！我们做了，服不服？）
在正文方法一节中，作者写到了怎么做出这三个变异株并在Vero细胞传代增殖的。这充分说明所合成改造过的病毒具有生物活性，不是伪（模拟）病毒。
Three recombinant SARS-CoV-2 mutants (N501Y, 102 Δ 69/70-N501Y+D614G, E484K+N501Y+D614G in spike protein) were prepared on the genetic 103 background of an infectious cDNA clone derived from clinical strain WA1 (2019- 104 nCoV/USA_WA1/2020) 5 by following the PCR-based mutagenesis protocol as reported 105 previously 7 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 . The full-length infectious cDNAs were in vitro ligated and used as templates to 106 transcribe full-length viral RNA. Mutant viruses (P0) were recovered on day 2 from Vero E6 cells 107 after electroporation of the in vitro RNA transcripts. P1 viruses were harvested as stocks by 108 passaging the P0 virus once on Vero E6 cells. The titers of P1 viruses were determined by 109 plaque assay on Vero E6 cells. The genome sequences of the P1 viruses were validated by 110 Sanger sequencing. The detailed protocol was recently reported 17 .”